title: US drug maker resisted changes to its opioid dosing recommendations to protect revenue, newspaper alleges.
authors.affiliation: Seattle.
authors.forename: Michael
authors.initials: M
authors.lastname: McCarthy
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D004345:Drug Industry / Q000191:economics*; D011307:Drug Prescriptions / Q000592:standards*; D006801:Humans; D010098:Oxycodone / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000701:Analgesics, Opioid; D010098:Oxycodone